“…Based on the low IL-33 levels, a known Th2 response promoter, it seems unlikely that the Th2 response was induced by this cytokine. Moreover, the importance of increased IL-17 and IL-22 levels compared to placebo remain to be elucidated as Frontiers in Drug Discovery frontiersin.org Author article, year Intervention/Patient population Outcome Saghari M, et al, 2022(Saghari et al, 2022 Intervention: Amlitelimab in HVs ↓ humoral response, ↓ skin rechallenge response Yang J, et al, 2021(Yang et al, 2021 Intervention: Acazicolcept in HVs ↓ humoral response Otterhaug T, et al, 2021(Otterhaug et al, 2021 Intervention: Fimaporfin+light in HVs ↑ humoral response Swaminathan A, et al, 2019(Swaminathan et al, 2019 Intervention: Solar UVR in HVs = humoral response, ↓ skin rechallenge response, ↑ Th17/CD4 + T cell ratio Poirier N, et al, 2016(Poirier et al, 2016 Intervention: VEL-101 in HVs ↓ humoral response Hostmann A, et al, 2015(Hostmann et al, 2015 Intervention: Oral KLH feeding in HVs Primed/Immunized subjects: = humoral response, = skin rechallenge response, ↓ CD4 + T cell, IL-2, IL-17, CLA, IFN-γ, ↑ CD4 + T cell, IL-10 Kaufman M, et al, 2014 (Kaufman et al, 2014) Intervention: Natalizumab in RRMS = humoral response (compared to no treatment) Gallegos A, et al, 2013(Gallegos et al, 2013 Intervention: MBSR in HVs ↓ humoral response (compared to HVs) Ferbas J, et al, 2013(Ferbas et al, 2013 Patient population: SLE vs. HVs Predominance of IgG2 followed by IgG1 after 2nd immunization (compared to predominance of IgG1 in HVs), = B cell ELISpot response Boulton C, et al, 2012(Boulton et al, 2012 Intervention: Fingolimod in HVs ↓ humoral response (compared to no treatment) Kapp K, et al, 2010(Kapp et al, 2010 Intervention: Oral KLH feeding in HVs Non primed/immunized subjects: faster and ↑ humoral response, = skin rechallenge response, ↑ CD4 + T cells, ↓ CD4 + CLA + T cells, faster ↑ in CD4 + T cells (including IL-2, IL-4, IFN-γ, TNF, and integrin β7 producing cells) and proliferated CD4 + T cells after immunization Primed/Immunized subjects: ↓ CD4 + T cell IL-2, IFN-γ, and TNF and ↑ CD4 + T cell IL-4 and IL-10, ↓ CD4 + CLA + T cells Bingham C, et al, 2010…”